| Metastatic Castration-Sensitive Prostate Carcinoma
Nubeqa vs Zytiga
Side-by-side clinical, coverage, and cost comparison for metastatic castration-sensitive prostate carcinoma.Deep comparison between: Nubeqa vs Zytiga with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZytiga has a higher rate of injection site reactions vs Nubeqa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zytiga but not Nubeqa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nubeqa
Zytiga
At A Glance
Oral
Twice daily
Androgen receptor inhibitor
Oral
Daily
CYP17 inhibitor
Indications
- Hormone refractory prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
- Metastatic castration-resistant prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
Dosing
Hormone refractory prostate cancer 600 mg (two 300 mg tablets) orally twice daily with food; continue until disease progression or unacceptable toxicity.
Metastatic Castration-Sensitive Prostate Carcinoma 600 mg (two 300 mg tablets) orally twice daily with food; when used with docetaxel for mCSPC, administer first of 6 cycles of docetaxel within 6 weeks of starting NUBEQA; continue NUBEQA until disease progression or unacceptable toxicity.
Metastatic castration-resistant prostate cancer 1,000 mg orally once daily with prednisone 5 mg orally twice daily; take on an empty stomach (no food 2 hours before or 1 hour after).
Metastatic Castration-Sensitive Prostate Carcinoma 1,000 mg orally once daily with prednisone 5 mg orally once daily; take on an empty stomach (no food 2 hours before or 1 hour after).
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Increased AST, decreased neutrophil count, increased bilirubin, fatigue, increased ALT (nmCRPC and mCSPC); constipation, rash, decreased appetite, hemorrhage, increased weight, hypertension (mCSPC with docetaxel).
Serious Febrile neutropenia (6%), decreased neutrophil count (2.8%), musculoskeletal pain (2.6%), pneumonia (2.6%), urinary retention, hematuria, arrhythmias, spinal cord compression, ischemic heart disease, heart failure.
Postmarketing COVID-19/COVID-19 pneumonia, myocardial infarction, sudden death, seizures, drug-induced liver injury.
Most common (>=10%) Fatigue, arthralgia, hypertension, nausea, edema, hypokalemia, hot flush, diarrhea, vomiting, upper respiratory infection, cough, headache
Serious Cardiac failure, hepatotoxicity, hypokalemia (Grade 3-4), arrhythmia, cardiorespiratory arrest
Postmarketing Non-infectious pneumonitis, myopathy including rhabdomyolysis, fulminant hepatitis including acute hepatic failure and death, QT prolongation and Torsades de Pointes, anaphylactic reactions
Pharmacology
Darolutamide is an androgen receptor (AR) inhibitor that competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. The major metabolite ketodarolutamide exhibits similar in vitro activity and decreased prostate cancer cell proliferation in vitro and tumor volume in xenograft models.
Abiraterone acetate is converted in vivo to abiraterone, a selective inhibitor of CYP17 (17alpha-hydroxylase/C17,20-lyase) that blocks androgen biosynthesis in testicular, adrenal, and prostatic tumor tissues, thereby reducing serum testosterone and other androgens in patients with prostate cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nubeqa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Zytiga
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Nubeqa
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Zytiga
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Nubeqa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zytiga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$10/momo
Janssen CarePath Savings Program: ZytigaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NubeqaView full Nubeqa profile
ZytigaView full Zytiga profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.